MSH2 and Lynch syndrome: IHC testing of MLH1, PMS2, MSH2, and MSH6 is recommended for all DS cancers of the Lynch syndrome spectrum including adenocarcinomas of the gastroesophageal junction, small bowel, and colorectum.